Synairgen will commence a Phase I trial with PXS-5382A, its lead compound from its LOXL2 inhibitor programme, in Q4 2017 following the completion of pre-clinical development. Data is expected mid-2018. The timelines are in line with expectations. Our recommendation and Target Price are currently under review. We will review both in due course.
06 Sep 2017
N+1 Singer - Synairgen - Lead LOXL2 compound on track to commence Phase I in Q4 2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Synairgen - Lead LOXL2 compound on track to commence Phase I in Q4 2017
Synairgen plc (SNG:LON) | 6.8 0 0.0% | Mkt Cap: 13.6m
- Published:
06 Sep 2017 -
Author:
Sheena Berry -
Pages:
3
Synairgen will commence a Phase I trial with PXS-5382A, its lead compound from its LOXL2 inhibitor programme, in Q4 2017 following the completion of pre-clinical development. Data is expected mid-2018. The timelines are in line with expectations. Our recommendation and Target Price are currently under review. We will review both in due course.